AR106227A1 - COMPOSITIONS AND METHODS TO INHIBIT THE GENE EXPRESSION OF THE APO APOLIPOPROTEIN GENE (a) (LPA) - Google Patents
COMPOSITIONS AND METHODS TO INHIBIT THE GENE EXPRESSION OF THE APO APOLIPOPROTEIN GENE (a) (LPA)Info
- Publication number
- AR106227A1 AR106227A1 ARP160103006A ARP160103006A AR106227A1 AR 106227 A1 AR106227 A1 AR 106227A1 AR P160103006 A ARP160103006 A AR P160103006A AR P160103006 A ARP160103006 A AR P160103006A AR 106227 A1 AR106227 A1 AR 106227A1
- Authority
- AR
- Argentina
- Prior art keywords
- lpa
- gene
- apo
- inhibit
- compositions
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen los agentes de interferencia de ARN (ARNi) y los conjugados de los agentes ARNi para inhibir la expresión del gen LPA (apo(a)). También se describen composiciones farmacéuticas que comprenden uno o más agentes de ARNi de LPA opcionalmente con uno o más agentes terapéuticos. La entrega de los agentes de ARNi de LPA descritos a las células hepáticas in vivo proporciona la inhibición de la expresión del gen LPA y el tratamiento de enfermedades cardiovasculares y cardiovasculares relacionadas.RNA interference agents (RNAi) and the conjugates of RNAi agents to inhibit the expression of the LPA gene (apo (a)) are described. Pharmaceutical compositions comprising one or more LPA RNAi agents optionally with one or more therapeutic agents are also described. The delivery of the described LPA RNAi agents to liver cells in vivo provides inhibition of LPA gene expression and the treatment of related cardiovascular and cardiovascular diseases.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562235816P | 2015-10-01 | 2015-10-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR106227A1 true AR106227A1 (en) | 2017-12-27 |
Family
ID=60923936
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160103006A AR106227A1 (en) | 2015-10-01 | 2016-09-30 | COMPOSITIONS AND METHODS TO INHIBIT THE GENE EXPRESSION OF THE APO APOLIPOPROTEIN GENE (a) (LPA) |
ARP210100996A AR121850A2 (en) | 2015-10-01 | 2021-04-15 | LPA RNA INTERFERENCE AGENT (RNAi), USE OF SAID AGENT AND METHOD FOR INHIBITING LPA EXPRESSION |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210100996A AR121850A2 (en) | 2015-10-01 | 2021-04-15 | LPA RNA INTERFERENCE AGENT (RNAi), USE OF SAID AGENT AND METHOD FOR INHIBITING LPA EXPRESSION |
Country Status (1)
Country | Link |
---|---|
AR (2) | AR106227A1 (en) |
-
2016
- 2016-09-30 AR ARP160103006A patent/AR106227A1/en unknown
-
2021
- 2021-04-15 AR ARP210100996A patent/AR121850A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
AR121850A2 (en) | 2022-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018003678A2 (en) | Compositions and methods to inhibit lpa gene expression | |
ECSP20017905A (en) | IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) | |
DOP2019000005A (en) | 3-METIL PIRAZINAS 2,5-DISUSTITUIDAS AND 3-METIL PIRAZINAS 2,5,6-TRISUSTITUIDAS AS ALLOSTERIC INHIBITORS OF SHP2 | |
CO2020001740A2 (en) | Iarn agents and compositions to inhibit the expression of angiopoietin type 3 (angptl3) and methods of use | |
CO2017004525A2 (en) | Ror-gamma inhibitory dihydropyrrolopyridines | |
GT201700167A (en) | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER. | |
MA43377A (en) | METHODS AND COMPOSITIONS RELATED TO TOXICITY ASSOCIATED WITH CELL THERAPY | |
UY37098A (en) | ROR-GAMMA MODULATORS | |
UY37565A (en) | IARN ALFA-1 ANTITRIPSIN AGENTS (AAT), COMPOSITIONS INCLUDING IARN AAT AGENTS AND METHODS OF USE | |
DOP2012000257A (en) | DERIVATIVES OF THE ACID 1-AMINO-2-CICLOPROPILETILBORONICO | |
EA201692318A1 (en) | COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE ALPHA-1-ANTITRIPSINE GENE | |
EA201792103A1 (en) | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HIF2ALPH GENES | |
CO2018002198A2 (en) | Pharmaceutical compositions comprising an oligomeric compound to modulate the expression of apolipoprotein (a) | |
ECSP20000655A (en) | IARN AGENTS FOR THE INHIBITION OF THE EXPRESSION OF ALFA-ENaC AND METHODS OF USE | |
AR106227A1 (en) | COMPOSITIONS AND METHODS TO INHIBIT THE GENE EXPRESSION OF THE APO APOLIPOPROTEIN GENE (a) (LPA) | |
DOP2014000221A (en) | METHODS TO TREAT CANCER USING PI3K INHIBITOR AND MEK INHIBITOR | |
AR113014A1 (en) | IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) | |
AR113454A1 (en) | IARN AGENTS AND COMPOSITIONS TO INHIBIT RECIPIENT EXPRESSION OF ASIALOGLYCOPROTEIN 1 | |
AR113254A1 (en) | IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF ANGIOPOYETIN TYPE 3 (ANGPTL3) AND METHODS OF USE | |
AR112754A1 (en) | IARN AGENTS FOR THE INHIBITION OF THE EXPRESSION OF a-ENaC AND METHODS OF USE | |
AR105611A1 (en) | RNAi THERAPY FOR HEPATITIS B VIRUS INFECTION | |
AR090580A1 (en) | PHARMACEUTICAL COMPOSITIONS FOR COMBINED THERAPY | |
AR096390A1 (en) | COMPOSITIONS OF ARNi DE SERPINA1 AND ITS METHODS OF USE | |
CU20120052A7 (en) | PIRAZOL DERIVATIVES THAT MODULATE ESTEAROIL-COA-DESATURASA |